Overall survival analyses of glioma patients from TCGA and CGGA were performed according to the median value of MAPKAPK2 as the cutoff point showed that high levels of MAPKAPK2 were correlated with poor prognosis of glioma patients (Figures 3F–H). This evidence concerns the gene MAPKAPK2 and glioma.